信达生物独家披露:四条战线,对垒诺和诺德、礼来

健识局
Jul 01

国产GLP-1越来越多了,怎么和外企竞争?这个话题被摆到台面上。6月30日,信达生物告诉健识局:公司将基于在公立医院渠道的已有优势,以及在医生群体中积累的口碑,积极布局公立与民营医院,同时重点布局线上、零售等创新渠道。信达生物的长效GLP-1产品玛仕度肽是6月27日获批的,首发适应症就是减重,这和司美格鲁肽、替尔泊肽都不一样:诺和诺德、礼来能从医院内分泌科渠道入手铺货,信达要想进医院,那也只能是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10